Compare JBGS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBGS | DVAX |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 2004 |
| Metric | JBGS | DVAX |
|---|---|---|
| Price | $18.04 | $10.72 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $16.50 | ★ $26.50 |
| AVG Volume (30 Days) | 722.3K | ★ 1.9M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $501,226,000.00 | $330,514,000.00 |
| Revenue This Year | N/A | $23.23 |
| Revenue Next Year | $1.79 | $16.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $13.28 | $9.20 |
| 52 Week High | $24.30 | $14.63 |
| Indicator | JBGS | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.29 | 45.28 |
| Support Level | $17.36 | $11.33 |
| Resistance Level | $18.69 | $11.58 |
| Average True Range (ATR) | 0.58 | 0.34 |
| MACD | 0.14 | -0.04 |
| Stochastic Oscillator | 60.69 | 0.00 |
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.